@article{APS8231,
author = {Shu-yong Zhang and Jing Li and Xin Xie},
title = {Discovery and characterization of novel smallmolecule agonists of G protein-coupled receptor 119},
journal = {Acta Pharmacologica Sinica},
volume = {35},
number = {4},
year = {2016},
keywords = {},
abstract = {Shu-yong ZHANG1, Jing LI2, Xin XIE1, 2, *
1Laboratory of Receptor-based Bio-medicine, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; 2CAS Key Laboratory of Receptor Research, the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Aim: GPR119 is a G protein-coupled receptor (GPCR) that is highly expressed in pancreatic β-cells and intestinal L-cells and facilitates glucose-stimulated insulin secretion (GSIS). GPR119 may represent a novel target for the treatment of metabolic disorders. Here, we sought to identify novel small-molecule GPR119 agonists.
Methods: A cell-based high-throughput screening assay was established using HEK293 cells stably expressing GPR119 and pCRE-luc reporter plasmid (HEK293/GPR119/pCRE-luc). A compound library composed of 1440 compounds was screened. Mouse β-cell line MIN-6 and isolated mouse islets were used to evaluate the effects of candidate compounds on GSIS in vitro.
Results: Three compounds with novel structures (ZSY-04, -06, and -13) were found to activate GPR119-mediated signaling and to induce GPR119 desensitization. The EC50 values of ZSY-04, -06, and -13 in stimulating intracellular cAMP accumulation in HEK293/GPR119 cells were 2.758, 3.046, and 0.778 µmol/L, respectively. Furthermore, all three compounds displayed high selectivity for GPR119, and did not activate other 9 GPCRs tested. Moreover, all three compounds significantly increased GSIS in both MIN-6 mouse β-cells and isolated mouse islets at concentration of 10 µmol/L.
Conclusion: Three novel small-molecule GPR119 agonists (ZSY-04, -06, and -13) with high receptor selectivity and capacity to induce GSIS in vitro were discovered. These compounds are potential candidates to be structurally optimized into drugs for the treatment of type 2 diabetes.
Keywords: GPCR; GPR119; PSN632408; AR231453; high-throughput screening; cAMP; Ca2+; β-cell; insulin; obesity; type 2 diabetes mellitus
This project was supported by grants from the Ministry of Science and Technology of China (2013ZX09507001, 2012ZX09301001-005, and 2014CB541906), the National Natural Science Foundation of China (81202341), and the Shanghai Commission of Science and Technology (12XD1402100 and 11ZR1408000).
* To whom correspondence should be addressed.
E-mail xxie@simm.ac.cn
Received 2014-02-22 Accepted 2014-03-05},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/8231}
}